Clinical trials: Post-exposure Prophylaxis
Corona Virus Infection, Acute Respiratory Distress Syndrome
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus
- Trial name
- COVID-19 PEP (NCT04308668)
- Testing
- Hydroxychloroquine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,312 people
- Sponsor
- University of Minnesota
Rabies
Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules
This study was planned to establish the non-inferiority of Rabipur administered as simulated post exposure Zagreb schedule as compared to Essen schedule, in healthy Indian adult subjects.
- Trial name
- NCT01365494
- Testing
- Purified Chick Embryo Cell Inactivated Rabies Vaccine
- Where
- 3 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Sexually Transmitted Diseases
Doxy-Post-exposure Prophylaxis
The goal of this project is to collect data regarding the ability of various oral doses of doxycycline to penetrate mucosal tissues in men and women to inform the combination of doxycycline with antiretrovirals (ARVs) for the…
- Trial name
- DOXY-PEP (NCT05853120)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Emory University
Rabies
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
This is a Phase 2b, double blinded, randomized study of SYN023 compared to HyperRab® (a licensed Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP).
- Trial name
- ARPEP (NCT03961555)
- Testing
- SYN023, HRIG (HyperRab), Rabies vaccine
- Where
- 14 sites in United States, Philippines
- Volunteers
- 448 people
- Sponsor
- Synermore Biologics Co., Ltd.
Anthrax
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax.
- Trial name
- NCT01491607
- Testing
- BioThrax
- Where
- 4 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077969
- Testing
- Famotidine, Celecoxib
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
SARS-CoV-2
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute…
- Trial name
- PROTECT-APT 1 (NCT05954286)
- Testing
- Upamostat
- Where
- 6 sites in United States, South Africa and 2 more
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
HIV
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.
- Trial name
- NCT01214759
- Testing
- Truvada, Raltegravir
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- The University of Texas Health Science Center, Houston
Leprosy
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which is ending in 2022.
- Trial name
- BE-PEOPLE P2 (NCT05406479)
- Testing
- BE-PEP (Bedaquiline), SDR-PEP, BE-PEP (Rifampicine)
- Where
- Comoros
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Hiv
Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study
Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
- Trial name
- DORAVIPEP (NCT04233372)
- Testing
- Delstrigo
- Where
- 2 sites in France, Spain
- Volunteers
- 399 people
- Sponsor
- Hospital Clinic of Barcelona
COVID-19, Corona Virus Infection
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons…
- Conditions
- COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
- Trial name
- NCT04328961
- Testing
- Hydroxychloroquine Sulfate, Ascorbic Acid
- Where
- 8 sites in United States
- Volunteers
- 943 people, healthy volunteers welcome
- Sponsor
- University of Washington
COVID-19, Viral Respiratory Illnesses
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.
- Trial name
- NCT04343248
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 4 sites in United States
- Volunteers
- 190 people
- Sponsor
- Romark Laboratories L.C.
COVID-19, SARS-CoV 2
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
- Trial name
- NCT04372017
- Testing
- Hydroxychloroquine, Vitamin D
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sanford Health
Pertussis
Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure
The purpose of this study is to compare the effectiveness of two strategies of post-exposure prophylaxis (PEP) in healthcare workers (HCWs) who have been vaccinated with acellular pertussis vaccine and have been exposed to…
- Trial name
- VPES (NCT00469274)
- Testing
- Antibiotic PEP
- Where
- United States
- Volunteers
- 1,102 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Leprosy
Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar
This is a cluster randomized trial on effectiveness of different modalities of Single Double Dose of Rifampicin Post-Exposure Prophylaxis (SDDR-PEP) for leprosy in the Comoros (Anjouan and Mohéli) and Madagascar.
- Trial name
- PEOPLE (NCT03662022)
- Testing
- Rifampicin
- Where
- 3 sites in Comoros, Madagascar
- Volunteers
- 144,000 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Anthrax
BARDA Securing Anthrax Immunity For the Elderly
This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable…
- Trial name
- B-SAFE (NCT03518125)
- Testing
- BioThrax, AV7909
- Where
- 4 sites in United States
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Anthrax
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine. The vaccine schedule and dose will also be assessed.
- Trial name
- NCT01770743
- Testing
- AV7909, BioThrax
- Where
- 4 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Anthrax
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
This study is designed to evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when administered orally, prior to, and following, the intramuscular (IM) administration of a two-dose schedule of AV7909…
- Trial name
- NCT04067011
- Testing
- Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909
- Where
- 4 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
HIV Infections
HIV Non Occupational Post-Exposure Prophylaxis (PEP)
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
- Trial name
- NCT00594646
- Testing
- TRUVADA + Raltegravir
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fenway Community Health